Atea Pharmaceuticals, Inc.

AVIR Nasdaq SEC CIK 1593899
Follow Atea Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32.2M +23.5% vs same quarter last year
EPS, diluted −$0.40 +24.5% vs same quarter last year
Operating cash flow −$28.9M +28.5% vs same quarter last year
Operating income −$34M +25.4% vs same quarter last year
Net income by quarter
−$33.2M
−$34.3M
−$37.2M
−$42M
−$44.5M
−$45.4M
−$32.9M
−$32.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$200M−$100M$0$100M$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$158M
FY24−$168M
FY23−$136M
FY22−$116M
FY21$121M
FY20−$10.9M
FY19−$14M
FY18−$9.1M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$122.9M
FY21−$87M
FY20$296.7M
FY19−$12.8M
FY18−$7.9M
FY17-